PRIMARY STUDY
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study
Key Findings: The synthetic pharmaceutical cannabinoid or THC analogue i.e. nabilone significantly reduces levodopa-induced dyskinesia in patients with Parkinson's Disease.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 7
Study Result: Positive
Study Location(s): United Kingdom
Year of Pub: 2001
Cannabinoids Studied: Pharma THC
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype I
Sub-Ratio: 1:0